Type of information: Series B financing round
Company: Orchard Therapeutics (UK)
Investors: Baillie Gifford (UK) ORI Capital Temasek (Singapore) Cowen Healthcare Investments (USA - NY) Juda Capital, Pavilion Capital (USA - NY) RTW Investments (USA - NY) 4BIO Capital (UK) F-Prime Capital (USA -MA) UCL Technology Fund (UK)
Amount: $110 million (£85 million)
Funding type: series B financing round
- Orchard Therapeutics is a privately-held clinical-stage biotechnology company based in the UK and in California. The company works in partnership with University College London, Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester and Central Manchester University Hospitals NHS Foundation Trust, the University of California Los Angeles and Boston Children’s Hospital.
In 2016, Orchard and UCLA were awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM) to advance the development of autologous ex-vivo lentiviral gene therapy in ADA-SCID.
- Proceeds of the Series B round will be used to rapidly progress Orchard’s pipeline, including the global launch of OTL-101, and to expand their manufacturing infrastructure and business development activity. Orchard’s lead product, OTL-101, is an autologous ex-vivo lentiviral gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID).
- OTL-101 has been granted Breakthrough Therapy Designation by the FDA and is currently in late stage clinical development. Orchard’s pipeline includes other clinical and pre-clinical stage transformative gene therapies for immune deficiencies, including X-linked chronic granulomatous disease (X-CGD) and metabolic diseases, including MPS-IIIA and MPS-IIIB (Sanfilippo syndrome type A and type B).
- • On December 20, 2017, Orchard Therapeutics announced the completion of an oversubscribed $110 million (£85 million) Series B financing. Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund. In conjunction with the financing, Simone Song, senior partner at ORI Capital, has been appointed to Orchard’s board of directors.
Therapeutic area: Rare diseases - Genetic diseases